OncologyBreast Neoplasms

Antibody-Drug Conjugates: The Platform That Ate Oncology

From 1 approval to 15: how the ADC platform reshaped every solid tumor type

SR-2026-007

EditorMara Voss

CopywritersEditorial Team

Coming Soon

Antibody-Drug Conjugates: The Platform That Ate Oncology

From 1 approval to 15: how the ADC platform reshaped every solid tumor type

Why We Are Covering This

ADCs now account for 15 FDA approvals and dominate oncology deal-making. Two agents launched in 2025 alone, and competitive logic has shifted from first-in-class to best-in-class payloads and linker technology.

What to Expect

You will understand the engineering differences between ADC platforms, how payload and linker technology determine clinical differentiation, and how to evaluate competitive positioning across the approval pipeline.

Be first when this report publishes

The Life Science Feed briefing covers every major trial readout, approval, and pipeline shift, weekly.

Get the briefing first

thelifesciencefeed.com · Special Report

SR-2026-00707/26

Solid Tumors

Bowhead Whale Longevity Genes Offer Clues for Cancer, Aging

Insights from the bowhead whale's exceptional lifespan and cancer resistance point to novel genetic pathways for human anti-aging and oncology research.

Prostatic Neoplasms

Prostate Care: Balancing Immediate Relief with Long-Term Retreatment

Managing benign prostatic hyperplasia requires weighing rapid symptom improvement against the need for future interventions. Clinicians must consider patient preference and disease progression.

Breast Neoplasms

Genetic Test Identifies Breast Cancer Patients Who May Avoid Chemotherapy

A genetic test can identify patients with early-stage, hormone receptor-positive, HER2-negative breast cancer who may safely forgo adjuvant chemotherapy.

Breast Neoplasms

Giredestrant Improves Breast Cancer Survival Regardless of Menopause

Giredestrant, an oral selective estrogen receptor degrader (SERD), demonstrated improved invasive disease-free survival in early breast cancer.

Antibody-Drug Conjugates: The Platform That Ate Oncology

Antibody-Drug Conjugates: The Platform That Ate Oncology

Be first when this report publishes

Related Articles